It's been an exciting year for Karana Biotech. We are always thrilled when we can help our clients achieve their strategic objectives and bring tangible value to their businesses. Just wanted to take the time to wish all our clients, colleagues, and friends a Happy Holidays and a great start to 2025. Reach out if you will be at JPM.
关于我们
Karana Biotech is a boutique life science advisory firm focused on providing clients thoughtful business development solutions to meet their strategic objectives. The founder of Karana Biotech, Meera Desai, is a seasoned pharmaceutical development executive with over 15 years of experience in drug development from discovery through commercialization with a proven track record in business development and alliance management including the negotiation of development and commercialization agreements valued at over $1 Billion.
- 网站
-
https://karanabiotech.com
Karana Biotech, LLC的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1 人
- 总部
- San Jose，CA
- 类型
- 自有
- 创立
- 2018
地点
-
主要
获取路线
US，CA，San Jose，95120
Karana Biotech, LLC员工
动态
-
Karana Biotech is honored to be part of the deal team that has now been selected as a Finalist for the 2024 Scrip Deal of the Year Award. Congratulations to the Protagonist and Takeda teams for collaborating on this transformative deal. #Dealmaking #BusinessDevelopment
We are very pleased to announce that Protagonist Therapeutics has been shortlisted for the 2024 Scrip Deal of the Year Award for our rusfertide co-commercialization agreement with Takeda. This transformative deal harnesses Protagonist’s innovative peptide technology and Takeda’s global commercialization expertise to accelerate our goal of delivering life-changing therapies for polycythemia vera patients. ? For 20 years, the Scrip Awards have brought together industry leaders to honor and celebrate the finest innovations and accomplishments in global biopharma.? ? We’re honored by this recognition of our strategic collaboration and grateful to our partners at Takeda. ? Learn more about this year’s #ScripAwards: https://lnkd.in/ev9Kv-5E #biopharma | #innovation
-
Karana Biotech is happy to share the news of Rezolute's Positive Topline results from the Phase 2 POC trial in DME. Looking forward to sharing the news at BIO.
Today we announced positive topline data from our Phase 2 study of RZ402 in patients with diabetic macular edema (DME). Check out the press release to learn more: https://bit.ly/3VbpXzi
-